ATE465172T1 - Peptidträger für die verabreichung von arzneimitteln - Google Patents
Peptidträger für die verabreichung von arzneimittelnInfo
- Publication number
- ATE465172T1 ATE465172T1 AT05730247T AT05730247T ATE465172T1 AT E465172 T1 ATE465172 T1 AT E465172T1 AT 05730247 T AT05730247 T AT 05730247T AT 05730247 T AT05730247 T AT 05730247T AT E465172 T1 ATE465172 T1 AT E465172T1
- Authority
- AT
- Austria
- Prior art keywords
- drug administration
- peptide carrier
- therapeutic agents
- delivery
- peptide
- Prior art date
Links
- 238000001647 drug administration Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 102000003896 Myeloperoxidases Human genes 0.000 abstract 1
- 108090000235 Myeloperoxidases Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55037304P | 2004-03-05 | 2004-03-05 | |
| US55953204P | 2004-04-05 | 2004-04-05 | |
| PCT/US2005/007442 WO2005087801A1 (en) | 2004-03-05 | 2005-03-03 | Peptide carrier for drug delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE465172T1 true ATE465172T1 (de) | 2010-05-15 |
Family
ID=34975528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05730247T ATE465172T1 (de) | 2004-03-05 | 2005-03-03 | Peptidträger für die verabreichung von arzneimitteln |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7429563B2 (de) |
| EP (1) | EP1730174B1 (de) |
| AT (1) | ATE465172T1 (de) |
| DE (1) | DE602005020755D1 (de) |
| WO (1) | WO2005087801A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010054699A1 (en) * | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
| US8906231B2 (en) | 2009-09-10 | 2014-12-09 | Lonza Biologics Plc | Method and system for polypeptide purification |
| WO2018222929A1 (en) * | 2017-05-31 | 2018-12-06 | Prism | Proteogenomics Research Institute For Systems Medicine | Enhanced targeted delivery of therapeutic agents |
| WO2020178574A1 (en) * | 2019-03-04 | 2020-09-10 | Bicyclerd Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018884A (en) | 1975-06-26 | 1977-04-19 | Hoffmann-La Roche Inc. | Fluorogenic materials and labeling techniques |
| US4897255A (en) | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4744981A (en) | 1985-10-17 | 1988-05-17 | Neorx Corporation | Trichothecene antibody conjugates |
| EP0329184A3 (de) | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimere und antimere Konjugation |
| US4988496A (en) | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5460961A (en) * | 1988-06-14 | 1995-10-24 | La Region Wallonne | Human myeloperoxidase and its therapeutic application |
| US5846799A (en) | 1988-06-14 | 1998-12-08 | La Region Wallone | Human myeloperoxidase and its therapeutic application |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| AU666853B2 (en) | 1991-04-05 | 1996-02-29 | Genentech Inc. | Platelet aggregation inhibitors having high specificity for GP IIbIIIa |
| US5981194A (en) | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| US5708009A (en) | 1993-12-21 | 1998-01-13 | Eli Lilly And Company | Methods of inhibiting myeloperoxidase activity |
| WO1998007848A1 (en) * | 1996-08-21 | 1998-02-26 | Teikoku Hormone Mfg. Co., Ltd. | Recombinant mpo fragment and method for assaying mpo autoantibody reaction site by using the same |
| CA2277519A1 (en) | 1997-01-10 | 1998-07-16 | Massachusetts Institute Of Technology | Treatments for neurotoxicity in alzheimer's disease by .beta.-amyloid peptides |
| JP2003525038A (ja) | 2000-02-08 | 2003-08-26 | ユニバーシティー オブ ブリティッシュ コロンビア | 治療薬をスクリーニングするための組成物および方法 |
| AU2001283740A1 (en) | 2000-08-17 | 2002-02-25 | University Of British Columbia | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
-
2005
- 2005-03-03 EP EP05730247A patent/EP1730174B1/de not_active Expired - Lifetime
- 2005-03-03 WO PCT/US2005/007442 patent/WO2005087801A1/en not_active Ceased
- 2005-03-03 AT AT05730247T patent/ATE465172T1/de not_active IP Right Cessation
- 2005-03-03 DE DE602005020755T patent/DE602005020755D1/de not_active Expired - Lifetime
-
2006
- 2006-09-01 US US11/514,578 patent/US7429563B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1730174A1 (de) | 2006-12-13 |
| US20070077239A1 (en) | 2007-04-05 |
| EP1730174A4 (de) | 2008-05-07 |
| DE602005020755D1 (de) | 2010-06-02 |
| WO2005087801A1 (en) | 2005-09-22 |
| EP1730174B1 (de) | 2010-04-21 |
| US7429563B2 (en) | 2008-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118007T1 (el) | Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων | |
| EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
| MY169272A (en) | Her2 antibody composition | |
| EA200870599A1 (ru) | Стабильные препараты лаквинимода | |
| EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| EA200870366A1 (ru) | Короткая внутренне сегментированная интерферирующая рнк | |
| BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
| MX2009005622A (es) | Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores. | |
| TW200621804A (en) | Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer | |
| CY1113115T1 (el) | Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες | |
| EA200401526A1 (ru) | Новые соединения и их применение | |
| WO2007085629A3 (en) | Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents | |
| CY1112185T1 (el) | Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη | |
| ATE506957T1 (de) | Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| DE602004014145D1 (de) | Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen | |
| ATE507827T1 (de) | Behandlung pervasiver entwicklungsstörungen | |
| YU68702A (sh) | Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka | |
| EA200700976A1 (ru) | Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой | |
| ATE465172T1 (de) | Peptidträger für die verabreichung von arzneimitteln | |
| EA200700403A1 (ru) | ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ | |
| EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| AU6011001A (en) | Novel lhrh-antagonists, production and use thereof as medicament | |
| BRPI0516922A (pt) | composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |